# Verastem Inc. (VSTM)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $261M  
**Price:** $3.76 (-1.57%)

> Verastem Inc. is a biopharmaceutical company that concentrates on developing and commercializing innovative cancer therapies. Its primary focus is on creating treatments targeting cancer cell survival and division pathways, specifically in hematologic malignancies and solid tumors. Key products in its pipeline include small molecule inhibitors that aim to disrupt cancer cell signaling and replication processes. Verastem Inc. plays a pivotal role within the healthcare and biotechnology sectors, contributing to advancements in precision medicine through its targeted therapies. Headquartered in Needham, Massachusetts, Verastem's research and development efforts are geared towards addressing unmet needs in oncology by providing new options for patients, thereby enhancing its importance in the biopharmaceutical market landscape. As it continues to make strides in cancer treatment, Verastem Inc. remains an integral player in the ongoing quest for more effective cancer solutions.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $31M | — | -$170M | -$209M | — |
| 2024 | $10M | — | -$115M | -$131M | — |
| 2022 | $3M | — | -$73M | -$74M | — |
| 2021 | $2M | — | -$61M | -$71M | — |
| 2020 | $89M | — | -$49M | -$68M | — |
| 2019 | $17M | — | -$132M | -$149M | — |
| 2018 | $27M | — | -$95M | -$72M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $246M | $189M | $57M | $205M | — |
| 2024 | $102M | $130M | -$29M | $89M | $41M |
| 2022 | $95M | $48M | $47M | $75M | $25M |
| 2021 | $109M | $21M | $88M | $21M | — |
| 2020 | $154M | $39M | $115M | $68M | — |
| 2019 | $145M | $138M | $7M | $44M | $35M |
| 2018 | $277M | $153M | $124M | $130M | $25M |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$138M | — | — |
| 2024 | -$105M | $28,000 | -$105M |
| 2023 | -$86M | — | — |
| 2022 | -$64M | — | — |
| 2021 | -$54M | $196,000 | -$54M |
| 2020 | -$34M | $33,000 | -$34M |
| 2019 | -$139M | $7,000 | -$139M |
| 2018 | -$75M | $2M | -$76M |
| 2017 | -$57M | — | — |
| 2016 | -$29M | $39,000 | -$30M |
| 2015 | -$46M | $211,000 | -$46M |

Source: [CompaniesByCap](https://companiesbycap.com/company/VSTM)